envafolimab

Home
Ligands
envafolimab

GtoPdb Ligand ID: 10492

Synonyms: Envida® | KN-035 | KN035

envafolimab is an approved drug (China (2021))

Comment: Envafolimab (KN035) is a chimeric (human/camelid) anti-PD-L1 nanobody that acts as an immune checkpoint inhibitor, and which is being developed by Alphamab Co [1]. Structurally it is a VH-Fc dimer, and does not contain variable light (VL) domains. It therefore has a reduced molecular size and offers more favourable physico-chemical properties than full-size monoclonal antibodies. X-ray crystal structures show that KN035 binds to the same surface on PD-L1 where the ligand interacts with its cognate receptor PD-1 (programmed death protein 1).
The peptide sequence of envafolimab's heavy chain returned no matches with patented peptide sequences in a Protein: BLAST search in September 2019.

No information available.

No information available.

Summary of Clinical Use
Envafolimab (KN035) has advanced to Phase 3 clinical evaluation (in combination with gemcitabine and oxaliplatin chemotherapy) in patients with biliary tract neoplasms and is in earlier phase trials in solid tumours of other tissue origin. Click here to link to ClinicalTrials.gov's full list of KN035 studies. First approval was granted in China in 2021, for the treatment of microsatellite instability-high (MSI-H) or deficient MisMatch Repair (dMMR) advanced solid tumours.

Summary of Clinical Use

Envafolimab (KN035) has advanced to Phase 3 clinical evaluation (in combination with gemcitabine and oxaliplatin chemotherapy) in patients with biliary tract neoplasms and is in earlier phase trials in solid tumours of other tissue origin. Click here to link to ClinicalTrials.gov's full list of KN035 studies. First approval was granted in China in 2021, for the treatment of microsatellite instability-high (MSI-H) or deficient MisMatch Repair (dMMR) advanced solid tumours.